Low advanced Glycation end product diet improves the central obesity, insulin resistance and inflammatory profiles in Ir
- PDF / 394,913 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 74 Downloads / 205 Views
RESEARCH ARTICLE
Low advanced Glycation end product diet improves the central obesity, insulin resistance and inflammatory profiles in Iranian patients with metabolic syndrome: a randomized clinical trial Razieh Goudarzi 1 & Meghdad Sedaghat 2 & Mehdi Hedayati 3 & Azita Hekmatdoost 1 & Golbon Sohrab 1 Received: 9 October 2019 / Accepted: 14 August 2020 # Springer Nature Switzerland AG 2020
Abstract The study aimed to investigate the effects of 8-weeks AGEs restricted diet on glycemic control as well as lipid profile, inflammatory and oxidative stress biomarkers and IR in overweight patients with Mets. In this randomized, controlled clinical trial 40 clients were randomly assigned to take either a low AGE (L-AGE) or a regular AGE (Reg-AGE) diet. Also, both groups were advised to follow an energy-restricted diet. At baseline and after 8-weeks of intervention, anthropometric parameters, dietary intake, plasma concentrations of malondialdehyde, carboxymethyllysine, TNF-α, hs-CRP and levels of serum glucose, lipid and insulin were assessed. AGEs restriction resulted in significant changes in mean differences levels of CML (p < 0.004), FBG (p < 0.01), HOMA-IR (p < 0.04), TNF-α (p < 0.01) and MDA (p < 0.02) in comparison to Reg-AGE. Moreover, weight (p < 0.0001) and WC (p < 0.001) significantly declined in the intervention group. Our results indicate that dAGEs restriction plus a low-calorie diet is superior to a low-calorie diet in amelioration of central obesity and IR at least partially through reduction of OS and inflammation in Mets subjects. Keywords Metabolic syndrome . Obesity . Advanced glycation end products . Inflammation . Insulin resistance . Fasting blood glucose
Introduction In recent decades, prevalence of metabolic syndrome (Mets) has become the main growing medical problem in the world which is characterized as a cluster of hyperglycemia, dyslipidemia, hypertension and abdominal obesity that when occurring together lead
ClinicalTrials.gov ID NCT03147339 * Golbon Sohrab [email protected]; https://clinicaltrials.gov/show/ NCT03147339 1
Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Sciences, 46, Hafezi St., Farahzadi Blvd., Shahrak Qods, P.O.Box: 19395-4741, Tehran, Islamic Republic of Iran
2
Internal Medicine Department, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3
Cellular and Molecular Endocrine Research Center, Research Institute For Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
to conflicting outcomes including developing type 2 diabetes mellitus (T2DM), cardiovascular diseases (CVD), cancer, infertility, dementia, chronic oxidative stress (OS) and inflammation [1, 2]. Interest in these diseases is easily justified when about 2025% of the world’s adult population has the Mets [2], and synergistic effects of its issues increase the risk of mortality more than each of
Data Loading...
